Peter Forsberg is an Oncology physician. OpenAlex indexes 213 publications with 1,031 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1721 E 19th Ave Ste 200
Denver, CO 802181242
Telephone
720-748-4800Provider last certified this registry record 25 Sept 2024.
Clinical trials
- Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Sponsor: SCRI Development Innovations, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20259 payments$14,820openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20259 payments$12,214openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202511 payments$10,905openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
88.7%CD38-directed Cytolytic Antibody84.7%Daratumumab100%Part B, office-administered≥20 patientsThalidomide Analog2.7%Revlimid38%Lenalidomide35%Pomalyst27%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
6.3%Serotonin-3 Receptor Antagonist4.1%Ondansetron hydrochloride94%Ondansetron Hcl6%Part D + Part B<11 patientsOsmotically acting laxatives2.2%Magnesium sulfate100%Part B, office-administered≥15 patientsDermatology
2.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor2.7%Acyclovir100%Part D≥50 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Prophylactic Dexamethasone Rescues Unrestrained Lymphocyte Expansion in Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
Biology of Blood and Marrow Transplantation
2025 - Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non‐Response
American Journal of Hematology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”